Oncosec Medical (ONCS) Commences Dosing of First Patient in KEYNOTE-890 Phase 2 Clinical Trial
Tweet Send to a Friend
OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that the first patient has been treated in KEYNOTE-890, a Phase 2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
